Pacific Biosciences reports Q4 loss

Biotech firm posts $40.4 million deficit in latest quarter

Published on Feb. 12, 2026

Got story updates? Submit your updates here. ›

Pacific Biosciences of California Inc. reported a loss of $40.4 million in its fourth quarter, or 13 cents per share. Adjusting for restructuring and amortization costs, the company's losses were 12 cents per share.

Why it matters

Pacific Biosciences is a prominent biotech firm based in Menlo Park, California, focused on genetic sequencing technology. The company's quarterly financial results are closely watched by investors and analysts as indicators of its overall business performance and future prospects.

The details

The Menlo Park, California-based company reported a loss of $40.4 million, or 13 cents per share, in the fourth quarter. Adjusting for restructuring and amortization costs, the company's losses were 12 cents per share.

  • Pacific Biosciences reported its Q4 2025 financial results on February 12, 2026.

The players

Pacific Biosciences of California Inc.

A biotech company based in Menlo Park, California that specializes in genetic sequencing technology.

Got photos? Submit your photos here. ›

The takeaway

Pacific Biosciences' Q4 financial results reflect the ongoing challenges facing the biotech industry, with the company reporting significant losses despite its focus on innovative genetic sequencing technology. The company's performance will be closely watched by investors as it navigates the competitive landscape and works to commercialize its products.